Understanding AGRN: A Potential Drug Target for Alzheimer's (G375790)

Target Name: AGRN

NCBI ID: G375790

AGRN

Understanding AGRN: A Potential Drug Target for Alzheimer's

AGRN (Alzheimer's disease-associated gene) is a gene that has been identified as a potential drug target in the field of Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide, and there is currently no cure. The AGRN gene has been shown to be involved in the development and progression of Alzheimer's disease, and researchers are investigating its potential as a drug target.

AGRN is a gene that encodes a protein known as alpha-synuclein. The alpha-synuclein protein is a hallmark of Alzheimer's disease, and is found in the brains of people with the disease. It is believed that the alpha-synuclein protein plays a role in the destruction of nerve cells in the brain, which is thought to contribute to the progressive neurodegeneration that occurs in Alzheimer's disease.

Research has shown that individuals with certain genetic variations in the AGRN gene are at an increased risk of developing Alzheimer's disease. These genetic variations have been identified as risk factors for the development of the disease, and further research is being conducted to investigate their role in the development and progression of the disease.

In addition to its role in the development of Alzheimer's disease, AGRN has also been shown to be involved in the regulation of the immune system. This is important because the immune system plays a role in the immune response to the alpha-synuclein protein, and is thought to be a potential target for drugs that can treat Alzheimer's disease.

Despite the promising research on AGRN, more research is needed to fully understand its role in the development and progression of Alzheimer's disease. Further studies are needed to investigate the effects of drugs that can target the AGRN gene, and to determine the best way to use these drugs to treat Alzheimer's disease.

In conclusion, AGRN is a gene that has been identified as a potential drug target in the field of Alzheimer's disease. Further research is needed to fully understand its role in the disease and to determine the best way to use it as a treatment.

Protein Name: Agrin

Functions: Heparan sulfate basal lamina glycoprotein that plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ) and directs key events in postsynaptic differentiation. Component of the AGRN-LRP4 receptor complex that induces the phosphorylation and activation of MUSK. The activation of MUSK in myotubes induces the formation of NMJ by regulating different processes including the transcription of specific genes and the clustering of AChR in the postsynaptic membrane. Calcium ions are required for maximal AChR clustering. AGRN function in neurons is highly regulated by alternative splicing, glycan binding and proteolytic processing. Modulates calcium ion homeostasis in neurons, specifically by inducing an increase in cytoplasmic calcium ions. Functions differentially in the central nervous system (CNS) by inhibiting the alpha(3)-subtype of Na+/K+-ATPase and evoking depolarization at CNS synapses. This secreted isoform forms a bridge, after release from motor neurons, to basal lamina through binding laminin via the NtA domain

The "AGRN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGRN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets